From: Nazaryan, Nona <Nona.Nazaryan@pfizer.com>

**Sent:** 12 May 2020 21:16

To: Brian Howes; Leah McBride; Nikita Harika; Katie Pearce; Kelly Wells

Subject: Blair PDF Legalization 13/May/NN-CST- 46364-84900

Attachments: GMP 277 H Aseptic South 2020-009.pdf

Follow Up Flag: Follow up Flag Status: Flagged

Attention: This email has originated from outside Blair Consular Services. Please take extra care when opening links or attachments even if you've verified the sender. If in doubt, contact the IT service desk.

Dear Brian and Team,

Please can you arrange for the enclosed documents to be legalised.

### All required details are below:

Recipient Country	Document Type (CPP, GMP etc)	Business Unit	Product Name	Authentication Required	Country of Authentication	Date Required by	Pfizer Ref No (please quote on invoice)	Recipient Details (Name, Address, Telephone. Email)
Chile	GMP	PBG (IMB)	ALPROSTADIL	Apostille	UK	03-Jun- 2020	46364- 84900	Name: Juan Ignacio Donoso Address: Av. Cerro el Plomo 5680, Torre 6, Piso 16, Las Condes, Santiago, Chile, Telephone: +5622412998 Email: juanignacio.donoso@pfizer.com



From: Blair Consular Services Vicky Comb Elizabeth House 28 Woodthorpe Road

Origin: LHR

TW15 2RH ASHFORD United Kingdom

Contact: +4401784254123

To: PFIZER CHILE JUAN DONOSO

CERRO EL PLOMO 5680 TORRE 6, FLOOR 16

Contact: JUAN DONOSO +56222412957 juanignacio donoso@pfizer com

**SANTIAGO LAS CONDES** 

L Chile

FT51 CL-SCL-SCL

Day

Ref: 1011007

Pce/Shpt Weight

Piece

1/1 0.5 kg



Contents: Documents, gene ral business







BE IT KNOWN that I, Sunita Kumeri of, 268 Bath Road, Slough, Berkshire United Kingdom a duly authorised Notary Public

### **CERTIFY** that

1. The signature set and subscribed to the certificate at the foot of the first page of the copy document annexed hereto is genuine having been subscribed thereto by Zoe Bruce whose identity I the Notary attest and who is duly authorised by Pfizer Limited ("the Company") to represent them in this matter, and

2. Zoe Bruce has thereby certified on behalf of the company that the Certificate of GMP Compliance of a Manufacturer issued to Pfizer Manufacturing Belgium

NV annexed hereto is a true copy of the original document,

SIGNED and sealed at 268 Bath Road, Slough, Berkshire aforesaid on 13th May 2020.

Sunita Kumeri Notary Public

**England and Wales** 

Protocol No. 13/20

ı	ADO							
_	(Convention de La	STILLE						
1.	Country: Pays / Pais: United Kingdom of Great Britain							
-	oreat Britain and North							
5	This public document  Le présent acte public / El presente documento público							
2.	Has been signed by							
	a été signé par ha sido firmado por	Sunita Kumeri						
3.								
	agissant en qualité de quien actúa en calidad de	Notary Public						
4.	Bears the seal / stamp of est revêtu du sceau / timbre de y está revestido del sello / timbre de							
		rtified Certificado						
5.	at London	6. the	14 May 2020					
7.	by Her Majesty's Principal Secretary of State for Foreign and Commonwealth Affairs							
8.	<b>Number</b> sous no / bajo el numero	APO-1906024						
9.	Seal / stamp Sceau / timbre Sello / timbre	10. Signatu Signature Firma	re R. James					
	TORK OF THE PROPERTY OF THE PR	i iiiid	PJ					
2								

This Apostille is not to be used in the UK and only confirms the authenticity of the signature, seal or stamp on the attached UK public document. It does not confirm the authenticity of the underlying document. Apostilles attached to documents that have been photocopied and certified in the UK confirm the signature of the UK official who conducted the certification only. It does not authenticate either the signature on the original document or the contents of the original document in any way.

If this document is to be used in a country not party to the Hague Convention of the 5th of October 1961, it should be presented to the consular section of the mission representing that country

To verify this apostille go to www.verifyapostille.service.gov.uk

3201378

## Federal Agency for Medicines and Health Products

CERTIFICATE NUMBER: BE/GMP/2020/009

# CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

#### Part 1

Issued following an inspection in accordance with:

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Belgium confirms the following:

The manufacturer: Pfizer Manufacturing Belgium NV

Site address: Rijksweg 12, Puurs, 2870, Belgium

Has been inspected under the national inspection programme in connection with manufacturing Has been inspected under the hatton with Art. 40 of Directive 2001/83/EC transposed in the following authorisation no. 277 H in accordance with Art. 40 of Directive 2001/83/EC transposed in the following

national legislation.

Article 12 bis, § 1 of the Law of 25th March 1964 related to the Medicinal Products national legislation:

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2020-01-29, it is considered that it complies with:

2020-01-29, 11 is constant and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC <sup>3</sup>

• The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC <sup>3</sup>

• The principal.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and this certificate reflect the compliance status if more than three years because the status of the manufacturing site at the time of the inspection noted above and the certification of the manufacturing site at the time of the inspection noted above and the certification of the manufacturing site at the time of the inspection noted above and the certification of the manufacturing site at the time of the inspection noted above and the certification of the inspection of the certification of the inspection noted above and the certification of t This certificate reflects the same and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date should not be relied. However, this period of validity may be reduced or extended using results. should not be reflect up a should not be reflect up a should not be reduced or extended using regulatory risk of that inspection. However, this period of validity may be reduced or extended using regulatory risk of that inspections by an entry in the Restrictions or Clarifying remarks for the restrictions of that inspection. He of that inspections of the Restrictions of Clarifying remarks field. This certificate is valid management principles by an entry in the Restrictions of Clarifying remarks field. This certificate is valid management principles and both Parts 1 and 2. The authenticity of this certificate may be verified only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified only when presented with all pages and both Parts 1 and 2. in EudraGMDP. If it does not appear, please contact the issuing authority.

Online EudraGMDP, Ref key: 86202

Issuance Date: 2020-04-22

Signatory: Mr. X. D. Cuyper

Page 1 of 3

I. Zoe Bruce, on being certify this docume

The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.  $\frac{1}{2}$  Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

 $<sup>^3</sup>$  These requirements fulfil the GMP recommendations of WHO.

### Human Medicinal Products

1 MA	NUFACTURING OPERATIONS							
1.1	1 Sterile products 1.1.1 Aseptically prepared (processing operations for the following dosage forms)							
	1 1 1 2 I vophilisates							
	g reial Requirements							
	7 Other: highly potent products/certain normones(en)							
	1.1.1.3 Semi-solids							
	Special Requirements							
	7 Other: highly potent products(en)							
	1.1.1.4 Small volume liquids							
	Special Requirements							
	7 Other: highly potent products/ certain hormones(en)							
	1.1.2 Terminally Sterilised (processing operations for the following dosage forms)							
	t the state of the							
	1.1.2.3 Small volume fiquids							
	1.1.3 Batch certification							
	dist of product types)							
1.3	Biological medicinal products (list of product types)							
1.5	13.1 Riological medicinal products (tist of product types)							
	1.3.1.2 Immunological products							
	1.3.1.5 Biotechnology products							
	1.3.1.6 Human or animal extracted products							
	Special Requirements							
	7 Other: low molecular weight heparin(en)							
	1.3.2 Batch Certification (list of product types)							
	1.3.2.2 Immunological products							
	1.3.2.5 Biotechnology products							
	1.3.2.6 Human or animal extracted products							
	1.3.2.0							

Clarifying remarks (for public users)

Inspected area: 'Aseptic Area South" / 1.3.1.2: formulation and filling only 1.3.1.5: formulation and filling only 1.3.1.6: formulation and filling only

2020-04-22

Name and signature of the authorised person of the Competent Authority of Belgium

in name of



Séverine Brasseur (Signature) 2020.04.23 09:57:03 +02'00'

Mr. Xavier De Cuyper Federal Agency for Medicines and Health Products Tel: +32 2 5284000

Fax: +32 2 5284001